Relapsed or Refractory Chronic Lymphocytic Leukemia

7 clinical trials · Condition

Record	Firm	Date
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia (NCT03755154)	Institut de Recherches Internationales Servier	2019-07-17
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL (NCT03739554)	Cyclacel Pharmaceuticals, Inc.	2019-01-25
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (NCT03734198)	French Innovative Leukemia Organisation	2018-12-19
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT03206918)	BeiGene	2017-03-09
A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT01578707)	Pharmacyclics LLC.	2012-06-01
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT00963105)	Celgene	2009-10-19

Every clearance here is in the API, with alerts when new ones post.